Clinical and genetic analysis of a family diagnosed with familial hypobetalipoproteinemia in which the proband was diagnosed with diabetes mellitus

Atherosclerosis

Volumn 239, Issue 2, 2015, Pages 552-556

  Wang, Xiaoli ^a   Wang, Dongdong ^a   Shan, Zhongyan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin like factor 3; Gene mutation; Hypobetalipoproteinemia

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANGIOPOIETIN; ANGPTL3 PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ANGIOPOIETIN LIKE 3 GENE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FAMILIAL HYPOBETALIPOPROTEINEMIA; FAMILY STUDY; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MISSENSE MUTATION; PRIORITY JOURNAL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 GENE; WESTERN BLOTTING; BLOOD; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HEPG2 CELL LINE; HEREDITY; HYPOBETALIPOPROTEINEMIA, FAMILIAL, APOLIPOPROTEIN B; MUTATION; NUCLEOTIDE SEQUENCE; PEDIGREE; PHENOTYPE; PROTECTION; RISK FACTOR; TWINS;

ADULT; ANGIOPOIETINS; BIOMARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DISEASES IN TWINS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEK293 CELLS; HEP G2 CELLS; HEREDITY; HUMANS; HYPOBETALIPOPROTEINEMIA, FAMILIAL, APOLIPOPROTEIN B; MALE; MUTATION; PEDIGREE; PHENOTYPE; PROTECTIVE FACTORS; RISK FACTORS; TRANSFECTION; TRIGLYCERIDES;

EID: 84923320463     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.02.031     Document Type: Article

References (19)

1. Schonfeld G., Lin X., Yue P. Familial hypobetalipoproteinemia: genetics and metabolism. Cell. Mol. Life Sci. 2005, 62(12):1372-1378.
2. Schonfeld G., Patterson B.W., Yablonskiy D.A., et al. Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J.Lipid Res. 2003, 44(3):470-478.
3. Cohen J., Pertsemlidis A., Kotowski I.K., et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 2005, 37(2):161-165.
4. Wu J., Kim J., Li Q., et al. Known mutations of apoB account for only a small minority of hypobetalipoproteinemia. J.Lipid Res. 1999, 40(5):955-959.
5. Musunuru K., Pirruccello J.P., Do R., et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N.Engl. J. Med. 2010, 363(23):2220-2227.
6. Pisciotta L., Favari E., Magnolo L., et al. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. Circ. Cardiovasc. Genet. 2012, 5(1):42-50.
7. Noto D., Cefalù A.B., Valenti V., et al. Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia. Arterioscler. Thromb. Vasc. Biol. 2012, 32(3):805-809.
8. Martin-Campos J.M., Roig R., Mayoral C., et al. Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation. Clin. Chim. Acta 2012, 413(5-6):552-555.
9. Minicocci I., Montali A., Robciuc M.R., et al. Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J.Clin. Endocrinol. Metab. 2012, 97(7):E1266-E1275.
10. Miida T., Hirayama S. Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events. Curr. Opin. Lipidol. 2010, 21(1):70-75.
11. Shimizugawa T., Ono M., Shimamura M., et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J.Biol. Chem. 2002, 277(37):33742-33748.
12. Shimamura M., Matsuda M., Yasumo H., et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 2007, 27(2):366-372.
13. Elias N., Patterson B.W., Schonfeld G. Invivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene. Arterioscler. Thromb. Vasc. Biol. 2000, 20(5):1309-1315.
14. Miyake Y., Kimura R., Kokubo Y., et al. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008, 196(1):29-36.
15. Tarugi P., Lonardo A., Gabelli C., et al. Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. J.Lipid Res. 2001, 42(10):1552-1561.
16. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J.Lipid Res. 1990, 31(3):545-548.
17. Romeo S., Yin W., Kozlitina J., et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J.Clin. Invest. 2009, 119(1):70-79.
18. Hall S.S. Genetics: a gene of rare effect. Nature 2013, 496(7444):152-155.
19. Inukai K., Nakashima Y., Watanabe M., et al. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem. Biophys. Res. Commun. 2004, 317(4):1075-1079.